Dr. Scott May, PhDEli Lilly and Company における VP of Chemistry, Synthetic Molecule Design & Developmentスピーカー
アジェンダセッション
Emerging Technologies in the Scale Up of Oligonucleotide Therapeutics
, 4:00pmセッションを見るDevelopment and Manufacture of Oligonucleotides via Enzymatic Ligation
, 3:45pmセッションを見る